FindTrial
Sign In

Myeloid growth factor

DRUG3 trials

Sponsors

St. Jude Children's Research Hospital, Emory University, Dana-Farber Cancer Institute

Conditions

Clear Cell SarcomaEwings SarcomaGerm Cell TumorsHepatoblastomaNeuroblastomaNon-rhabdomyosarcoma Soft Tissue SarcomaOsteosarcomaRefractory Ewing Sarcoma

Phase 1

Simvastatin With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors
CompletedNCT02390843
Emory UniversityClear Cell Sarcoma, Ewings Sarcoma, Germ Cell Tumors +9
Start: 2015-02-28End: 2019-09-22Updated: 2020-04-03
Cabozantinib With Topotecan-Cyclophosphamide
CompletedNCT04661852
Dana-Farber Cancer InstituteRefractory Ewing Sarcoma, Refractory Osteosarcoma, Relapsed Ewing Sarcoma +1
Start: 2020-12-23End: 2022-10-24Updated: 2023-02-15

Phase 2

Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy
Active, not recruitingNCT01871766
St. Jude Children's Research HospitalRhabdomyosarcoma
Start: 2013-12-04End: 2030-06-30Updated: 2025-12-17

Related Papers

RMS13: A phase II trial using risk adapted focal proton beam radiation and/or surgery with the addition of maintenance chemotherapy in intermediate risk rhabdomyosarcoma.
Journal of Clinical Oncology2024-06-011 citations
Risk-adapted local therapy and intensive chemotherapy in patients with high-risk rhabdomyosarcoma.
Journal of Clinical Oncology2022-06-01
A phase I study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors.
Journal of Clinical Oncology2020-05-202 citations